Seoul, South Korea, May 23, 2021 / PRNewswire / – Hyundai Bioscience (KOSDAQ 048410) announced on the 24th that CNPharm, its leading biotech company, published an article containing the research results of CP-COV03, an oral niclosamide treatment for COVID-19 based on proprietary oral formulation technology, in a special issue of Medicines.
This article reveals the in vivo study of CNPharm, where they administered a single dose of CP-COV03 to rats, and therefore, the maximum concentration of the drug in the blood (Cmax) was approximately 300 times the IC50 level. , while maintaining the drug concentration level at or above 50% viral inhibition (IC50) for 24 hours. CP-COV03 has been recognized worldwide as a candidate for a ‘game-changing’ treatment that could compete with other oral antiviral drugs for COVID-19 developed by Merck, Pfizer and Roche, or Tamiflu which was an oral drug developed for the H1N1 pandemic.
In particular, the 300-fold difference between Cmax and IC50 concentrations confirmed by an in vivo study is an indicator that the therapeutic window of this drug is wide enough not only to increase its chances of success as an antiviral drug, but also to get the attention of Big Pharma who needed such game-changing drugs for COVID-19.
Now, Hyundai Bioscience is ready to conduct clinical trials in Korea and internationally for CP-COV03 based on the results of CNPharm’s preclinical studies, and has announced its intention to simultaneously seek opportunities for collaboration or licensed with global pharmaceutical companies. Roche, one of the largest pharmaceutical companies, has licensed Tamiflu, an H1N1 flu game changer, from Gilead. The clinical game-changing COVID-19 antiviral drugs by Roche and Merck have also been licensed by other original developers.
Niclosamide, the API (active pharmaceutical ingredient) of CP-COV03, not only inhibits viral replication like other game-changing antiviral drugs do, but it also breaks down and clears the virus in the cell as well as prevention lung damage caused by the coronavirus. These additional mechanisms were recently reported by articles published in Nature, suggesting that niclosamide is a promising COVID-19 drug candidate.
Without advanced biotechnology, it is almost impossible to maintain the concentration of niclosamide in the blood at or above the IC50 level for 24 hours with a single dose. No such success story has been reported to date, with the exception of one nasal inhalation formulation undergoing clinical trials in the United States. Cambridge University, which reached the IC50 for 24 hours only in lung tissue.
Last year, CNPharm developed the antiviral drug, CP-COV03, dramatically improving the bioavailability of niclosamide, which had been the biggest obstacle for 60 years in the reuse of niclosamide with extremely low absorption rate in the body. and one half too short. lifetime of drug concentration in the blood.
It should be noted that Dr. Jin-ho choy, Chief Scientist of CNPharm, recently drew the attention of Asian researchers at the ‘Science Council of Asia‘(SCA) conference held at Guangzhou, China, at May 13 and on the 14th, where he presented the efficacy results of CP-COV03 from a hamster model. His research team reported a study titled “ COVID-19 Game Changer Drug ” which found excellent antiviral efficacy of CP-COV03. Dr Choy, a full professor at Dankook University in Korea, is a member of the Korea National Science Assembly as well as the Korean Academy of Science and Technology.
Medicines, in which this research article is published, is a monthly Science and Technology Journal Citation Index (SCI) published by the Multidisciplinary Digital Publishing Institute (MDPI), one of the four leading academic publishers in the world. MDPI’s impact factor is 4.286 and it is a world-renowned journal that ranks in the 1st quartile (Q1) in Pharmacology and Pharmaceuticals.
About Hyundai Bioscience
HYUNDAI BIOSCIENCE is a biotechnology company that develops and markets bio-fusion technology with the aim of delivering active ingredients safely and effectively to targeted areas of the body. Hyundai Bioscience Organic-Inorganic Hybrid Technology is a new drug delivery system technology that enables selective and efficient delivery of active substances to the target area in combination with bio-friendly delivery vehicles. Applying its technology in the areas of tumor-targeted drugs and even skin and scalp care, Hyundai Bioscience will continue to expand its business scope by introducing innovative biotechnologies and new effective products.
View original content to download multimedia: http: //www.prnewswire.com/news-releases/a-game-changer-covid-19-drug-from-korea-was-introduced-in-a-world-class -academic -journal-301297452.html
SOURCE Hyundai Bioscience